Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Azevan Pharmaceuticals Inc.
DescriptionMixed Vasopressin 1a/1b receptor antagonist
Molecular Target Vasopressin 1a (V1a) receptor ; Vasopressin 1b (V1b) receptor
Mechanism of ActionVasopressin 1 (V1) receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard Indication Neurology (unspecified)
Indication DetailsTreat mood disorders
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today